Related Experiment Video
Updated: Dec 23, 2025

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
Published on: May 14, 2018
"Mitotic Slippage" and Extranuclear DNA in Cancer Chemoresistance: A Focus on Telomeres
Kristine Salmina1, Agnieszka Bojko2, Inna Inashkina1
1Cancer Research Division, Latvian Biomedicine Research and Study Centre, LV-1067 Riga, Latvia.
Abstract:
Mitotic slippage (MS), the incomplete mitosis that results in a doubled genome in interphase, is a typical response of TP53-mutant tumors resistant to genotoxic therapy. These polyploidized cells display premature senescence and sort the damaged DNA into the cytoplasm. In this study, we explored MS in the MDA-MB-231 cell line treated with doxorubicin (DOX). We found selective release into the cytoplasm of telomere fragments enriched in telomerase reverse transcriptase (hTERT), telomere capping protein TRF2, and DNA double-strand breaks marked by γH2AX, in association with ubiquitin-binding protein SQSTM1/p62. This occurs along with the alternative lengthening of telomeres (ALT) and DNA repair by homologous recombination (HR) in the nuclear promyelocytic leukemia (PML) bodies. The cells in repeated MS cycles activate meiotic genes and display holocentric chromosomes characteristic for inverted meiosis (IM). These giant cells acquire an amoeboid phenotype and finally bud the depolyploidized progeny, restarting the mitotic cycling. We suggest the reversible conversion of the telomerase-driven telomere maintenance into ALT coupled with IM at the sub-telomere breakage sites introduced by meiotic nuclease SPO11. All three MS mechanisms converging at telomeres recapitulate the amoeba-like agamic life-cycle, decreasing the mutagenic load and enabling the recovery of recombined, reduced progeny for return into the mitotic cycle.
Insights
TP53-mutant cancer cells undergoing mitotic slippage (MS) release damaged telomeres into the cytoplasm. These cells then use alternative lengthening of telomeres (ALT) and inverted meiosis (IM) to recover and restart cell division.
Area of Science:
- Cell Biology
- Genetics
- Cancer Research
Background:
- Mitotic slippage (MS) is a cellular response in TP53-mutant tumors resistant to genotoxic therapy, leading to a doubled genome.
- Polyploid cells resulting from MS exhibit premature senescence and cytoplasmic DNA damage.
- Doxorubicin (DOX) is a genotoxic agent used in cancer therapy.
Purpose of the Study:
- To investigate the mechanisms of mitotic slippage (MS) in the MDA-MB-231 cell line treated with doxorubicin (DOX).
- To understand how TP53-mutant cancer cells cope with DNA damage and polyploidy.
- To explore the role of telomere maintenance and meiosis in cancer cell recovery.
Main Methods:
- Treatment of MDA-MB-231 cells with doxorubicin (DOX).
- Analysis of telomere fragments, DNA double-strand breaks (γH2AX), and associated proteins (hTERT, TRF2, SQSTM1/p62) in the cytoplasm.
- Investigation of alternative lengthening of telomeres (ALT), homologous recombination (HR), and promyelocytic leukemia (PML) bodies.
- Observation of meiotic gene activation, holocentric chromosomes, and inverted meiosis (IM).
Main Results:
- Selective release of telomere fragments enriched in hTERT, TRF2, and γH2AX into the cytoplasm, associated with SQSTM1/p62.
- Concomitant activation of ALT and HR within nuclear PML bodies.
- Induction of meiotic genes and holocentric chromosomes, leading to inverted meiosis (IM) in repeated MS cycles.
- Formation of giant, amoeboid cells that bud off depolyploidized progeny, restarting mitotic cycling.
Conclusions:
- Mitotic slippage involves a reversible conversion from telomerase-based telomere maintenance to ALT, coupled with IM at sub-telomere breakage sites induced by SPO11.
- These converging mechanisms at telomeres mimic an amoeba-like life cycle, reducing mutagenic load.
- The process enables the recovery of recombined, reduced progeny for re-entry into the mitotic cycle, facilitating cancer cell survival and therapy resistance.
More Related Videos
09:13Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells
Published on: January 17, 2019
08:34Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
Related Concept Videos
Replication in Eukaryotes
Many Proteins Orchestrate Replication at the Origin
Eukaryotic replication follows many of the same...
Replication in Eukaryotes
Telomeres and Telomerase
Telomeres and Telomerase
Replicative Cell Senescence
Treatment Resistant Cancers